VBL Therapeutics nosedives after Ofra-Vec late-stage trial fails

Notable Labs

19/07/2022 23:29

** Drug developer's shares  VBLT.O  slump 77.8% to 46 cents
in extended trading after co announced late-stage trial results
of Ofra-Vec, its potential ovarian cancer treatment 
    ** VBLT is the biggest decliner across exchanges after the
bell
    ** Says the phase 3 trial did not meet the primary endpoints
in patients with platinum-resistant ovarian cancer  urn:newsml:reuters.com:*:nGNX1DBBNX
    ** VBLT says it plans to discontinue the trial, to review
data from ongoing mid-stage trials in metastatic colorectal
cancer and recurrent glioblastoma multiforme to determine next
steps for its lead oncology product candidate
    ** Stock down 4.1% YTD

 (Reporting by Shreyaa Narayanan and Ahmed Farhatha in
Bengaluru)
 ((Shreyaa.Narayanan@thomsonreuters.com))